BioCryst Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Charles K. Gayer
- Full Time Employees
- 435
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4505 Emperor Boulevard Durham NC United States of America 27703
- IPO Date
- Mar 4, 1994
- CIK
- 0000882796
- Website
- biocryst.com
- Similar Companies
- Business
- BioCryst Pharmaceuticals, Inc. is a biotechnology company specializing in the development and commercialization of oral small-molecule and protein therapeutics primarily targeting rare diseases. The company's core products include ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor used for the prophylaxis and treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older; RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza; and various pipeline candidates such as BCX9930, an oral Factor D inhibitor for complement-mediated diseases, and BCX9250, an oral ALK-2 inhibitor for fibrodysplasia ossificans progressiva (FOP). BioCryst's commercial offerings focus on rare genetic and complement system diseases, with ongoing clinical programs advancing novel therapies for conditions including Netherton syndrome and diabetic macular edema (DME). Founded in 1986 and headquartered in Durham, North Carolina, BioCryst operates globally, with a strategic emphasis on expanding access to its therapies worldwide. The company targets specialty healthcare providers and patients afflicted by rare and serious conditions, leveraging advanced medicinal chemistry and biological sciences to deliver transformative oral and injectable drugs. Recent major company developments include the completion of the sale of its European ORLADEYO business as part of a strategic refocus on core markets, and ongoing regulatory activities such as the FDA's review of ORLADEYO oral granules for pediatric use with an expected decision in December 2025. This pediatric indication expansion aims to broaden the accessible patient population significantly. BioCryst also reported a robust revenue increase driven by ORLADEYO, projecting full-year 2024 revenues of approximately $450.7 million and targeting profitability milestones by the end of 2025. The company is advancing its pipeline with clinical data expected in 2025 from programs such as BCX17725 for Netherton syndrome and avoralstat for DME. Additionally, BioCryst entered a $700 million acquisition deal for Astria, underscoring its commitment to deepening its rare disease portfolio. BioCryst continues to emphasize a people-focused approach alongside scientific innovation to meet unmet medical needs in hereditary angioedema and other rare disease areas. Its goal is to sustain strong growth of ORLADEYO while diversifying its pipeline toward market expansion and long-term profitability.
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Report First Quarter 2026 Financial Results on May 6